The cannabinoid industry is transitioning from early-stage exploration to scientifically validated, regulatory-backed ...

Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba®).

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet ( ...

VANCOUVER, BC / / June 20, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that the Co-Founders of its ...

On 6 June 2025, the European Commission launched a targeted stakeholder consultation on the classification and regulation of ...

Regulatory information management (RIM) software tools streamline global regulatory processes on a single cloud-based ...

SMO outlines Japan's advantages as a potential clinical trial site, in terms of services and regulatory landscape.

Europe conference, which took place between 29 and 30 April in Barcelona, Spain, industry experts delivered comprehensive ...

Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...